Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 11 of 6351
-
Can a new ultrasound technique spot hidden pancreatic cancers earlier?
Diagnosis By invitation onlyIn this study, LINFU® will be evaluated in patients who have been identified with IPMN to determine if it can be used to help identify early, pancreatic ductal adenocarcinoma and its noninvasive precursor lesions (dysplasia). The study will also help determine if LINFU® results i…
Sponsor: Adenocyte, LLC • Aim: Diagnosis
Last updated Aug 08, 2026 00:03 UTC
-
Massive global trial aims to find best stroke treatments
Disease control Recruiting nowStroke is causing 6.6 million deaths and is a major cause of disability worldwide in 2019. There remains an urgent need for interventions that improve outcomes which can be implemented with wide applicability for stroke. ACT-GLOBAL is a multi-factorial, multi-arm, multi-stage, ra…
Phase 3 • Sponsor: The George Institute • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat leukemia
Cure Recruiting nowThe purpose of the study is to evaluate the safety and tolerability of B019 in subjects.
Phase 1 • Sponsor: Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. • Aim: Cure
Last updated Aug 19, 2026 00:00 UTC
-
Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
Cure Recruiting nowThe purpose of this study is to test the safety and effectiveness of a sequence of drugs (a Taxane plus Trastuzumab plus Pertuzumab followed by Trastuzumab Deruxtecan, followed by Tucatinib plus Ado-Trastuzumab Emtansine (T-DM1), followed by Trastuzumab plus Pertuzumab plus Tucat…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Cure
Last updated Aug 08, 2026 00:03 UTC
-
Can a pill combo outperform standard therapy for a Hard-to-Treat lung cancer?
Disease control Recruiting nowThis Phase 3 study will evaluate the efficacy of JAB-21822+JAB-3312 versus tislelizumab (PD-1 Ab) combined with pemetrexed+carboplatin as the first line treatment in subjects with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
Phase 3 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a One-Time cell therapy silence lupus?
Cure Recruiting nowThe study is a single-arm, open-label clinical trial intended to recruit 6 refractory SLE subjects who meet the inclusion and exclusion criteria. The subjects will receive IM19 CAR-T cell infusion therapy at a dose of 1×10\^6/kg or 1×10\^8 CAR-T cells . The primary endpoint is to…
Sponsor: Peking University Third Hospital • Aim: Cure
Last updated Sep 02, 2026 00:00 UTC
-
Can a single dose of tafenoquine finally cure vivax malaria in southeast asia?
Cure Recruiting nowTafenoquine was recently approved by regulatory authorities in the USA and Australia. Tafenoquine is an alternative radical curative treatment to primaquine acting against the dormant liver stage of Plasmodium vivax (the hypnozoite). Tafenoquine (an 8-aminoquinoline) has the subs…
Phase 4 • Sponsor: University of Oxford • Aim: Cure
Last updated Jul 31, 2026 00:00 UTC
-
Can a One-Time gene infusion rewrite the fate of PKU?
Cure Recruiting nowThis is a Phase 1/2, open-label, multiple-center, dose escalation and cohort expansion study to evaluate the safety and efficacy of NGGT002 in adult subjects with classic Phenylketonuria (PKU). NGGT002 is a rAAV8 based vector carrying a functional copy of the human PAH gene. Par…
Phase 1/2 • Sponsor: NGGT (Suzhou) Biotechnology Co., Ltd. • Aim: Cure
Last updated Aug 15, 2026 00:00 UTC
-
Can a One-Time gene edit stop glaucoma in its tracks?
Cure PausedThis study is intented to evaluate the safety, tolerability and preliminary efficacy of CRISPR/Cas9 Instantaneous Gene Editing Therapy (BD113 virus-like particle, also BD113vLVP) in patients with primary open-angle glaucoma (POAG) with elevated intraocular pressure and MYOC gene …
Sponsor: Shanghai BDgene Co., Ltd. • Aim: Cure
Last updated Aug 22, 2026 00:00 UTC
-
Can a Two-Pill HIV prevention strategy outsmart the virus?
Prevention Recruiting nowThe purpose of this study is to evaluate the efficacy, acceptability, and safety of a simplified event-driven pre-exposure prophylaxis of HIV based on oral TAF/FTC in HIV-uninfected cisgender men who have sex with men (MSM). Primary objective: To assess the efficacy of emtricita…
Phase 3 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Prevention
Last updated Sep 04, 2026 00:00 UTC
-
Can Lab-Grown brain cells replace what Parkinson's destroys?
Cure Recruiting nowTo evaluate the safety and efficacy of transplantation of human induced pluripotent stem cell-derived dopaminergic progenitors, CT1-DAP001, into the corpus striatum in patients with Parkinson's disease
Phase 1 • Sponsor: University of California, San Diego • Aim: Cure
Last updated Aug 19, 2026 00:00 UTC
-
Hepatitis b cure breakthrough? new combo aims for 50%+ cure rate
Cure Recruiting nowExploring the safety and efficacy of the therapy combining immune checkpoint inhibitors (anti-PD-L1 monoclonal antibody, ASC22) and pegylated interferon alfa (Peg-IFNα) in patients with CHB. Exploring new combination therapeutic schemes for hepatitis B cure, and raising the overa…
Phase 4 • Sponsor: The Second Affiliated Hospital of Chongqing Medical University • Aim: Cure
Last updated Sep 03, 2026 00:00 UTC
-
Can a One-Two punch of CAR-T and lenalidomide beat tough leukemia?
Cure Recruiting nowThis is a Phase I/II interventional, open-label treatment study designed to evaluate the safety and efficacy of concomitant therapy with anti-CD19 CAR T-cells and Lenalidomide in adult patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who have been pretreated w…
Phase 1/2 • Sponsor: Vitebsk Regional Clinical Cancer Centre • Aim: Cure
Last updated Aug 15, 2026 00:00 UTC
-
Gene therapy trial aims to stop duchenne in its tracks
Disease control Recruiting nowThis is a multicenter, open-label, non-randomized study to investigate the safety, tolerability, and efficacy of a single intravenous (IV) infusion of SGT-003 in participants with Duchenne muscular dystrophy. There will be 5 cohorts in this study. Cohort 1 will include participan…
Phase 1/2 • Sponsor: Solid Biosciences Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug combo aims to cure breast cancer that has spread to just a few places
Cure Recruiting nowThe study will include patients with HER2-positive breast cancer and 1- 3 distant metastatic lesions, all amenable for curative intervention. Patients will be stratified by prior therapy and ER expression. In the initial baskets patients with be treated with trastuzumab-deruxteca…
Phase 2 • Sponsor: The Netherlands Cancer Institute • Aim: Cure
Last updated Jun 27, 2026 08:00 UTC
-
Gene therapy trial offers hope for babies with rare, deadly metabolic disease
Disease control Recruiting nowOrnithine Transcarbamylase (OTC) deficiency, the most common urea cycle disorder, is an inherited metabolic disorder caused by a genetic defect in a liver enzyme responsible for detoxifying of ammonia. Individuals with OTC deficiency can develop elevated levels of ammonia in the …
Phase 3 • Sponsor: iECURE, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can matching treatment to genetic risk beat relapsed childhood leukemia?
Cure Recruiting nowThis study is open-label, multi-center, prospective study, which targets childhood patients with relapsed acute lymphostatic leukemia including bone marrow recurrence. Aim of this study is to investigate the outcome of NGS MRD based risk stratified treatment for relapsed acute ly…
Phase 2 • Sponsor: Ho Joon Im • Aim: Cure
Last updated Jul 31, 2026 00:00 UTC
-
Can a new drug pair beat standard chemotherapy for tough AML?
Disease control Recruiting nowThis is an open-label, multicenter, phase 2b, randomized study aiming to compare the efficacy and safety of venetoclax plus azacytidine Versus daunorubicin plus cytarabine (conventional 7+3 regimen) in adult acute myeloid leukemia (AML) patients with adverse risk featuress. Parti…
Phase 2/3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat lymphomas
Cure Recruiting nowThis is a non-randomized clinical trial to evaluate the safety and efficacy of CD22CART administered after lymphodepleting chemotherapy in adults with relapsed / refractory B Cell Lymphomas. All evaluable participants will be followed for overall survival (OS), progression free s…
Phase 1 • Sponsor: Stanford University • Aim: Cure
Last updated Aug 14, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat leukemias
Cure CompletedThis study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of targeting CD123 CAR-NK cell preparations in Relapsed/refractory acute myeloid leukemia (AML) or blastocytic plasmacytoid dendritic cell neoplasm …
Phase 1/2 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Cure
Last updated Aug 07, 2026 00:00 UTC